High demand makes Novo Nordisk hit the brakes on Wegovy
Access to the lowest doses of the obesity treatment is temporarily reduced in the US due to ”higher than expected volume growth.”
by christopher due karlsson, translated by daniel pedersen
Danish drugmaker Novo Nordisk is experiencing such high demand for its type 2 diabetes treatment Ozempic and highly sought-after weight-loss therapy Wegovy – both of which are based on the same substance, semaglutide – that access to the latter’s lowest doses will be limited.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg)
